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nation diet is indeed standard of care.1 Compliance with the
6-food elimination diet in real-world settings is understandably
low. Some recommend repeat EGDs at each step of the elimina-
tion diet, for up to 5 EGDs per patient,2 at an immense burden
to patients and expense to the health care system.
My review also revealed that the most common food trig-
ger was dairy.3 This seemed a perfect situation for an un-
blinded n-of-1 trial. The condition is chronic. Response to food
elimination varies by individual. The symptoms are experi-
enced near daily. And if I was going to eliminate a food from
my diet for the rest of my life, I wanted to know for certain that
it was the cause of my symptoms.
I eliminated all milk products from my diet for 8 weeks.
My symptoms resolved. I then ate bread pudding with ice
cream, sweet butter on my corn, and milk in my cereal. My
symptoms recurred. I am now off dairy, symptom free, and con-
vinced I know my food trigger. No further EGDs.
At the end of my trial, I read the article by Kravitz and
colleagues4 that demonstrated a lack of effectiveness of pa-
tients randomized to n-of-1 trials compared with usual care for
treatment of chronic musculoskeletal pain. This was a laud-
able negative study that advanced the science of n-of-1 trials.
Still, my experience suggests there may yet be a role for n-of-1
trials. My hope is that the study by Kravitz and colleagues spurs
other researchers and clinicians not to abandon n-of-1 trials,
but rather animates us to think creatively about scenarios in
which n-of-1 trials might simplify treatment regimens, im-
prove patient compliance, and reduce health care costs.
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In Reply The letters from Vohra and Punja and Smith about
our recent Original Investigation1 underscore the same
crucial point: patients may vary not only in their response
to treatment, but also in their response to n-of-1 trials.
Vohra and Punja offer an ardent counterpoint to Mirza and
Guyatt’s conclusion that n-of-1 trials are a “beautiful idea
being vanquished by cruel and ugly evidence.”2(1379) Smith’s
story offers an inspiring example of how n-of-1 trials may be
applied informally in the service of better, more patient-
centered care.
More generally, we believe that rumors of the demise of
n-of-1 trials may be premature for 3 reasons. First, advances
in mobile technology and ubiquitous home and environmental
sensors will increasingly make tracking and self-experimen-
tation much less demanding of time and effort on the part of
both patients and clinicians. Second, n-of-1 trials retain prom-
ise not only for evaluating treatment benefits in individual pa-
tients, but also (as Vohra and Punja suggest) for comparing
treatments of comparable efficacy that may differ in terms of
costs or harms. Finally, we believe that n-of-1 trials have not
yet been fully appreciated as an instrument for advancing sci-
entific literacy and self-efficacy. Broad deployment of n-of-1
trials evaluating health behaviors such as diet, exercise, medi-
cation adherence, and stress reduction may not only show
people how to be healthier, they might also teach them about
the power of randomization, the importance of systematic out-
comes assessment, and the need to minimize bias—concepts
that are not only central to science and data literacy, but ulti-
mately fundamental to democracy.
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Finding Benefit in n-of-1 Trials
To the Editor The recent article by Kravitz and colleagues1 re-
porting the results of a randomized clinical trial comparing n-
of-1 trials with standard care for treatment of chronic muscu-
loskeletal pain raises a number of interesting issues that merit
further examination.
Weighedonacontinuumofprobability, it iscertainlypossible
that there is a positive effect of these trials on pain interference
score, which is unlikely to be because of chance alone based on
the observed results; however, this effect is not demonstrated to
the arbitrary level that is customary for statistical significance.
This speaks directly to 2 points: (1) the P value standards we set
are subjective and should be viewed not as dichotomous yes/no
evidence, but as a continuum of probability as put forth in the
American Statistical Association statement on P values,2 and (2)
the clinical significance of the findings of this trial are ignored in
favor of identifying statistical superiority for pain-interference
score. The stated goal of the authors was to establish the “ben-
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efits of participating in an n-of-1 trial, not to assess the superior-
ity or inferiority of any particular treatment.”1(1369) The improve-
mentinshareddecisionmakingregardingmedicationsisperhaps
even more meaningful than a narrow statistical focus on pain in-
terference score as an outcome owing to the mistrust of health
care professionals that has become pervasive in the medical sys-
tem and litigation that is a prominent feature of US medicine.
Becauseresultswereinfavorofthen-of-1armfortheprimary
outcomeandthestatisticalanalysiswasclosetoourstandardlev-
els of significance (P = .09), the shortfall in recruitment and miss-
ing data may have important consequences in passing the ac-
cepted threshold. Owing to the inordinate focus on P value, it’s
unclear if a 1-sided statistical test would have provided the stan-
dard (arbitrary) level of statistical significance and completely
reversed the overall interpretation of the results. Another prob-
lem is the usage of a 2-sample t test for ordinal pain scores, which
by their discrete nature are not normally distributed, violating
basic assumptions of this hypothesis test. A permutation or
Wilcoxon signed rank test may have produced significant results
at the .05 level for a difference in pain score reduction.
The study by Kravitz and colleagues1 reported higher in-
cidences of a 5-point pain score reduction, which may have re-
sulted in statistical significance between groups using this as
a primary outcome. The study also reported increased discus-
sion from the patients and clinicians for the intervention group,
with a P value of .01 for differences discussion scores at 6
months and a P value of .05 for 12-month discussion scores.
These results actually suggest that n-of-1 trials show some
promise for pain management, which warrants further inves-
tigation. Therefore, it is quite premature to conclude so thor-
oughly, as is done in the accompanying Invited Commentary,
that “the results fail to show any benefit of n-of-1 care.”3(1378)
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To the Editor We read with interest the recent article by Kravitz
and colleagues1 describing a randomized clinical trial compar-
ing n-of-1 trials with standard care for treatment of chronic mus-
culoskeletal pain.
The goal of the study was to establish the “benefits of
participating in an n-of-1 trial, not to assess the superiority
or inferiority of any particular treatment.”1(1369) However,
there appears to be a disconnect between the study goal and
the choice of outcomes, which were focused on pain inter-
ference scores across different treatment regimens. There-
fore, the null results should be interpreted with respect to
treatment efficacy, not design. The n-of-1 participants who
demonstrated a better response to 1 of 2 treatments were
likely to experience improved pain outcomes as a result of
continuing to receive the superior treatment. However, there
was a high proportion (>75%) of n-of-1 participants who had
no treatment superiority, and this may explain the trial’s
findings.
Methodological factors, including the number and length of
phases,couldhaveinfluencedthedegreeofcertaintyabouttreat-
ment superiority. Individual n-of-1 trials were heterogeneous,
ranging from 4 to 12 weeks and with phases lasting 1 to 2 weeks.
Some n-of-1 trials could have involved few crossovers, which
mighthaveaffectedtheidentificationofasuperiortreatmentand
increased the risk of type-2 error. Furthermore, there was a lack
of blinding, and the study did not achieve its sample size target,
which may have influenced the results.
A total of 48% of n-of-1 participants incorporated non-
pharmacological treatment into their n-of-1 trials. Designing
phases that are long enough to show an effect (if one exists)2
is a relatively easy task for n-of-1 pharmacological trials ow-
ing to well-known drug half-lives, but this is more difficult in
nonpharmacological trials (eg, exercise, acupuncture) where
one must hypothesize about the immediacy and duration of
effect.3 As such, 1 to 2 weeks is potentially too short.
Finally, the findings assume that participants adhered to
the superior or recommended treatments. Lack of adherence
could influence the effectiveness of interventions, and adher-
ence rates may vary across different intervention types; ad-
herence may be better for simple interventions (eg, daily medi-
cation) compared with more complex ones (eg, regular
exercise). Nonadherence could have influenced the study find-
ings, but this does not appear to have been explored.
Clinically meaningful results favoring the n-of-1 group were
underemphasized, and between-subject variability in re-
sponse to treatment was not reported. This was an ambitious
but valuable study, which has illustrated a number of key is-
sues for the field. We should avoid throwing the baby out with
the bathwater4 and instead capitalize on the contribution this
study makes to optimize future n-of-1 research.
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In Reply Many of the questions raised by Chapple and Blackston
and by McDonald and colleagues about our recent Original
Investigation1 are addressed in Pocock and Stone’s recent review
on what to do when the primary outcome fails.2 Certainly, a trial
inwhichtheprimaryoutcomefallsshortofstatisticalsignificance
can be distressing to investigators. However, as highlighted by
Chapple and Blackston, the interpretation of trial results may be
colored by undue attention to a single primary outcome and ar-
bitrary P value cut points. These constraints make sense in con-
firmatory studies of new drugs and devices (where the conse-
quences of false positives can be dire) but not necessarily in more
exploratory studies (like the Personalized Research for Monitor-
ing Pain Treatment study3).
Both letters raise a number of other methodological is-
sues, including lack of statistical power, underemphasis of im-
portant secondary outcomes, problems with application of the
n-of-1 intervention, and potentially poor patient adherence.
As we noted in our article,1 the study fell 12% short of enroll-
ment goals, but it is not clear that reaching the planned sample
size of 244 would have resulted in a significant P value. Single
studies rarely provide definitive estimates of effect size, and
for this reason we believe further studies (and subsequent
meta-analyses) are warranted.
We agree that statistically significant between-group differ-
ences were seen in medication-related shared decision making
and in the probability of achieving a 5-point pain interference
score reduction. These findings are clinically important and de-
serving of further study. Likewise, although certain n-of-1 trial
design choices (eg, offering nonpharmacologic treatments and
relatively short treatment periods) may have contributed to the
large proportion of inconclusive n-of-1 trials, our goal was to bal-
ance experimental rigor with patient choice and convenience.
Finally, although patients randomized to the n-of-1 arm ad-
hered well to their assigned treatment regimens (averaging 1.4
on a 1-5 scale, with 1 indicating “always” following the di-
rected treatment), we did not track adherence to the “win-
ning” treatment following the trial. If the benefit of n-of-1 trial
participation (if any) is mediated purely through the identifi-
cation of clinically superior treatments, poor adherence to the
“winner” in the aftermath of an n-of-1 trial could, as McDonald
and colleagues suggest, limit the potential benefit. However,
we suspect that other potential mechanisms are operative
(eg, creating a more therapeutic physician-patient relation-
ship, enhancing patients’ self-efficacy as autonomous agents)
and may deserve more attention than previously recognized.
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Inconsistencies in Reporting Studies
of Lactic Acidosis
To the Editor In their recently published Original Investigation re-
garding metformin use, renal function, and acidosis, Lazarus and
colleagues1 explainedwhytheirfindingsweredifferentthanours2
and wrote that our study “was limited by sparse [estimated glo-
merular filtration rate] data and did not account for changes in
[estimated glomerular filtration rate] over time.”1(909) This is not
true. Table 2 in our article2 summarized that we were able to clas-
sify more than 90% of metformin exposure time to renal
function. In addition, our methods section clearly stated that we
determined renal function during follow-up time and ran our
analysis using a time-varying Cox regression analysis in which
we modeled both changes in metformin exposure and changes
in renal function over calendar time.
Nevertheless, because both studies1,2 used routine health
care data, renal function recordings were probably a proxy in-
dicator of the true renal function during the development of
lactic acidosis. A more sensible explanation for the differ-
ences between the studies is that Lazarus and colleagues1 were
more likely to measure metabolic or respiratory acidosis in-
stead of lactic acidosis. The authors used International Clas-
sification of Diseases, Ninth Revision, Clinical Modification codes
to define their outcome. This coding system, in contrast with
UK Read terminology, cannot define lactic acidosis; there-
fore, we feel that the words lactic acidosis should have been
replaced by acidosis. In a recently published follow-up letter,
Lazarus and colleagues3 wrote that our study2 evaluated aci-
dosis. This is not true either; we evaluated the risk of lactic aci-
dosis.
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